18. Rebranding and Shifting Strategies
As public and regulatory scrutiny of opioids intensified, some pharmaceutical companies rebranded themselves or pivoted to new products, such as addiction treatments or non-opioid painkillers. These strategic shifts, described by Bloomberg, often focused on reputation management and profit retention, rather than addressing the root causes or ongoing harm created by their earlier opioid marketing practices.
